While age alone is not a contraindication for using Sotoxen, elderly Sotoxen 120 mg (Sotorasib) patients may have additional considerations that need to be taken into account when determining the appropriateness of treatment. These considerations may include age-related changes in organ function, potential comorbidities, and the presence of other medications that the patient may be taking.
Elderly patients often have altered pharmacokinetics and pharmacodynamics compared to younger adults, which can affect how medications are metabolized and how they may respond to treatment. As a result, healthcare providers may need to adjust the dosage of Sotoxen or closely monitor elderly patients for any signs of toxicity or adverse effects.
Despite these considerations, Sotoxen may be a suitable treatment option for some elderly patients with KRAS G12C-mutated NSCLC, especially if they are otherwise healthy and have a good performance status. Clinical trials evaluating the safety and efficacy of Sotoxen have included patients across a wide age range, including elderly individuals, and have demonstrated promising results in this population.